Tokio Marine Asset Management Co. Ltd. Purchases 111 Shares of Humana Inc. (NYSE:HUM)

Tokio Marine Asset Management Co. Ltd. grew its position in shares of Humana Inc. (NYSE:HUM) by 4.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,731 shares of the insurance provider’s stock after acquiring an additional 111 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Humana were worth $1,250,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of HUM. Exchange Traded Concepts LLC raised its stake in shares of Humana by 103.0% during the third quarter. Exchange Traded Concepts LLC now owns 2,883 shares of the insurance provider’s stock valued at $1,403,000 after acquiring an additional 1,463 shares during the last quarter. Caprock Group LLC raised its stake in Humana by 3.6% in the third quarter. Caprock Group LLC now owns 1,421 shares of the insurance provider’s stock worth $693,000 after buying an additional 50 shares in the last quarter. UMB Bank n.a. raised its stake in Humana by 2.8% in the third quarter. UMB Bank n.a. now owns 805 shares of the insurance provider’s stock worth $392,000 after buying an additional 22 shares in the last quarter. Czech National Bank raised its stake in Humana by 46.4% in the third quarter. Czech National Bank now owns 21,656 shares of the insurance provider’s stock worth $10,536,000 after buying an additional 6,866 shares in the last quarter. Finally, Aaron Wealth Advisors LLC bought a new position in Humana in the third quarter worth about $213,000. 92.38% of the stock is owned by institutional investors.

Humana Stock Performance

HUM stock traded down $4.41 on Friday, hitting $307.00. The company had a trading volume of 109,332 shares, compared to its average volume of 1,980,397. Humana Inc. has a 12-month low of $299.23 and a 12-month high of $541.21. The company has a current ratio of 1.67, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77. The stock’s 50-day simple moving average is $328.56 and its 200 day simple moving average is $395.71. The stock has a market cap of $37.04 billion, a price-to-earnings ratio of 19.39, a P/E/G ratio of 1.85 and a beta of 0.45.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company had revenue of $29.61 billion for the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter last year, the company posted $9.38 earnings per share. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. As a group, equities research analysts expect that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.15%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio is currently 22.04%.

Insider Buying and Selling

In other Humana news, Director Jorge S. Mesquita purchased 545 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the transaction, the director now owns 2,578 shares of the company’s stock, valued at $946,358.02. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.32% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

HUM has been the subject of a number of research reports. Oppenheimer decreased their price target on shares of Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a research note on Thursday. Bank of America reissued a “neutral” rating and issued a $342.00 price target (down from $470.00) on shares of Humana in a research note on Tuesday, April 2nd. Stephens decreased their price target on shares of Humana from $550.00 to $430.00 and set an “overweight” rating for the company in a research note on Friday, January 26th. Barclays decreased their target price on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 2nd. Finally, Jefferies Financial Group decreased their target price on shares of Humana from $411.00 to $381.00 and set a “buy” rating for the company in a research note on Monday. Eleven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus target price of $433.74.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.